Theranos, a Palo-Alto blood-testing company, has no material revenue, no more than $200 million in cash, 220 employees, and plenty of legal troubles, according to the Wall Street Journal. Theranos has not set aside funds for "any potential liability," according to the Journal. After all, the Journal reported that just two lawsuits -- Partner Fund Management alleges Theranos made misleading statements in soliciting its investment and Walgreens charges breach of contract against Theranos -- seek to recover $240 million in damages. Since the Journal exposed cracks in its story, things have gotten less comfortable for Theranos. [And Theranos] said it is cooperating with the probes and appealing the regulatory sanctions, which are on hold pending the outcome of those proceedings," according to the Journal.

Source: Forbes February 17, 2017 14:03 UTC